Oppenheimer started coverage on shares of Millendo Therapeutics (NASDAQ:MLND) in a research note released on Tuesday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $26.00 target price on the stock. Oppenheimer also issued estimates for Millendo Therapeutics’ Q2 2019 earnings at ($0.83) EPS, Q3 2019 earnings at ($0.86) EPS, Q4 2019 earnings at ($0.87) EPS, FY2019 earnings at ($3.33) EPS, FY2020 earnings at ($4.11) EPS, FY2021 earnings at ($5.41) EPS, FY2022 earnings at ($5.93) EPS and FY2023 earnings at ($4.66) EPS.

Several other research analysts also recently weighed in on MLND. ValuEngine downgraded shares of Welbilt from a hold rating to a sell rating in a research report on Wednesday, June 12th. Citigroup set a $12.00 price target on shares of Controladora Vuela Co Avcn SA CV and gave the stock a buy rating in a research report on Monday, July 15th. Finally, Zacks Investment Research upgraded shares of Golub Capital BDC from a hold rating to a buy rating and set a $20.00 price target for the company in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Millendo Therapeutics has an average rating of Buy and an average target price of $24.38.

MLND opened at $10.51 on Tuesday. Millendo Therapeutics has a twelve month low of $6.77 and a twelve month high of $17.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.83 and a current ratio of 7.83. The stock’s 50-day moving average is $12.56. The firm has a market cap of $142.56 million, a P/E ratio of -0.60 and a beta of 2.61.

Millendo Therapeutics (NASDAQ:MLND) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.08). As a group, sell-side analysts expect that Millendo Therapeutics will post -3.27 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Private Advisors LLC raised its holdings in Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after acquiring an additional 1,279 shares during the last quarter. Geode Capital Management LLC acquired a new stake in Millendo Therapeutics in the 4th quarter valued at about $113,000. Tibra Equities Europe Ltd acquired a new stake in Millendo Therapeutics in the 1st quarter valued at about $303,000. BlackRock Inc. acquired a new stake in Millendo Therapeutics in the 4th quarter valued at about $203,000. Finally, Worth Venture Partners LLC acquired a new stake in Millendo Therapeutics in the 4th quarter valued at about $206,000. Institutional investors own 44.07% of the company’s stock.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

See Also: How do buyers and sellers choose a strike price?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.